进展期结直肠癌动脉灌注新辅助化疗临床疗效观察

Objective To evaluate the curative effect of neoadjuvant chemotherapy via arterial infusion on advanced colorectal carcinoma. Methods One hundred and twenty-eight advanced colorectal carcinoma patients in stage Ⅱ B or Ⅲ were randomly divided into 2 groups. Sixty-eight cases received preoperative arterial infusion chemotherapy( the treatment group),and chemotherapy regimen consist of Oxaliplatin(L-OHP) 130 mg/m2, Hydroxycamptothecin (HCPT) 20 mg/m2 and Dexifluridine (FUDR)600 mg/m2. Femoral arterial infusion chemotherapy administrated 8 ～ 14 days preoperative. Sixty cases received surgery directly(the control group). The adverse reaction and histology effect after arterial infusion chemotherapy were observed, and resection rate,complications,pathology stage,together with long term survival were compared. Results Adverse reaction were mostly grade Ⅰ -Ⅱ gastrointestinal discomfort and bone marrow depression with arterial infusion chemotherapy. Resection rate was 97. 1% (66/68) ,and 64 cases(96. 9%) underwent raclical (R0) resection in the treatment group, which were higher than those in the the control group(73. 3%(44/60) and 79. 5%,respectively) (x2 = 14. 848,8. 906, Ps ＜ 0. 05). Histology effect of the treatment group was 72. 7%, and the pathology stage downstaged compared to preopeartion. Percent of patients in stage Ⅱ in the treatment group was higher than that in the control group( P ＜ 0. 05). The median survival time of test group was 53. 0 months, 1- ,3-,and 5-year survival rates were 95.3%,85.9% and 44.6%, respectively. In the control group, the median survival time was 42.0 months, 1-, 3-, and 5-year survival rates were 92.6%, 75.9% and 22.0%,respectively. There was significant difference in 5-year survival rate(x2 = 6. 385, P ＜ 0. 05). No difference in postoperative complications between two groups(P ＞ 0. 05). Conclusion The neoadjuvant chemotherapy via arterial infusion is of great significance on downstnging the pathology of advanced colorectal carcinoma, raising the excision rate, especially radical resection, and long term survival rate.     

Clincal research of HA program combimed co-α-2b interferon on treatment of chronic myeloid leukemia

Objective To observe the HA program (3 harringtonine and Ara-C) co-α-2b interferon treatment of chronic myeloid leukemia in the feasibility and safety. Methods In our hospital from December 2005 to January 2009 out-patient and hospitalization in patients with CML were randomly assigned according to the principle of 51 cases were divided into 26 cases of the observation group and control group 25 cases. The control group were treated with α-2b interferon 3 × 106U subcutaneously or intramuscularly 3 times per week,intramuscularly 1 to 12 months to ease later changed to 2 times per week to maintain; treatment group therapy in the control group based on the GC small dose of HA programs: subcutaneous injection of Ara-C 20 mg,every 12 h one time; homoharringtonine alkaline 2 mg/d plus 5 % glucose solution 500 mL, by intravenous infusion over 4 h,in conjunction with the 7 ～ 14 d for a course of treatment monthly repeated a times, after 12 months depending on the circumstances every 2 to 3 months a time. Results The observation group and the control group,hematological remission total effective rates were 96.15% (25/26) and 72.0% (18/25),the observation group than the control group,2 group, the difference was significant (P<0.05); the observation group cytogenetic response overall response rates were 76.92% (20/26) and 20.0% (5 / 25), the observation group cytogenetic response overall response rate than the control group, 2 group, the difference was significant sex (P<0.05);two groups of patients with adverse reactions can be tolerated, does not affect the treatment. Conclusion Small dose of HA regimen combined with recombinant in terferon α-2b treatment of CML than single recombinant interferon α-2b high efficacy, with lower white blood cell effects of apparent high rate of hematologic response, no increase in adverse reactions and survival prolonged and so on.     

Clincal research of HA program combimed co-α-2b interferon on treatment of chronic myeloid leukemia

Objective To observe the HA program (3 harringtonine and Ara-C) co-α-2b interferon treatment of chronic myeloid leukemia in the feasibility and safety. Methods In our hospital from December 2005 to January 2009 out-patient and hospitalization in patients with CML were randomly assigned according to the principle of 51 cases were divided into 26 cases of the observation group and control group 25 cases. The control group were treated with α-2b interferon 3 × 106U subcutaneously or intramuscularly 3 times per week,intramuscularly 1 to 12 months to ease later changed to 2 times per week to maintain; treatment group therapy in the control group based on the GC small dose of HA programs: subcutaneous injection of Ara-C 20 mg,every 12 h one time; homoharringtonine alkaline 2 mg/d plus 5 % glucose solution 500 mL, by intravenous infusion over 4 h,in conjunction with the 7 ～ 14 d for a course of treatment monthly repeated a times, after 12 months depending on the circumstances every 2 to 3 months a time. Results The observation group and the control group,hematological remission total effective rates were 96.15% (25/26) and 72.0% (18/25),the observation group than the control group,2 group, the difference was significant (P<0.05); the observation group cytogenetic response overall response rates were 76.92% (20/26) and 20.0% (5 / 25), the observation group cytogenetic response overall response rate than the control group, 2 group, the difference was significant sex (P<0.05);two groups of patients with adverse reactions can be tolerated, does not affect the treatment. Conclusion Small dose of HA regimen combined with recombinant in terferon α-2b treatment of CML than single recombinant interferon α-2b high efficacy, with lower white blood cell effects of apparent high rate of hematologic response, no increase in adverse reactions and survival prolonged and so on.     

Significance of 125I radioactive seed implantation on growth differentiation factor and programmed death receptor-1 during treatment of oral cancer

BACKGROUND Oral cancer(OC)is the most common malignant tumor in the oral cavity,and is mainly seen in middle-aged and elderly men.At present,OC is mainly treated clinically by surgery or combined with radiotherapy and chemotherapy;but recently,more and more studies have shown that the stress trauma caused by surgery and the side effects of radiotherapy and chemotherapy seriously affect the prognosis of patients.AIM To determine the significance of 125I radioactive seed implantation on growth differentiation factor 11(GDF11)and programmed death receptor-1(PD-1)during treatment of OC.METHODS A total of 184 OC patients admitted to The Second Affiliated Hospital of Jiamusi University from May 2015 to May 2017 were selected as the research subjects for prospective analysis.Of these patients,89 who received 125I radioactive seed implantation therapy were regarded as the research group(RG)and 95 patients who received surgical treatment were regarded as the control group(CG).The clinical efficacy,incidence of adverse reactions and changes in GDF11 and PD-1 before treatment(T0),2 wk after treatment(T1),4 wk after treatment(T2)and 6 wk after treatment(T3)were compared between the two groups.RESULTS The efficacy and recurrence rate in the RG were better than those in the CG(P<0.05),while the incidence of adverse reactions and survival rate were not different.There was no difference in GDF11 and PD-1 between the two groups at T0 and T1,but these factors were lower in the RG than in the CG at T2 and T3(P<0.05).Using receiver operating characteristic(ROC)curve analysis,GDF11 and PD-1 had good predictive value for efficacy and recurrence(P<0.001).CONCLUSION 125I radioactive seed implantation has clinical efficacy and can reduce the recurrence rate in patients with OC.This therapy has marked potential in clinical application.The detection of GDF11 and PD-1 in patients during treatment showed good predictive value for treatment efficacy and recurrence in OC patients,and may be potential targets for future OC treatment.     

α1-receptor blockers combined with acupuncture treatment efficacy analysis of elderly patients with acute urinary retention

Objective To explore acupuncture and al-receptor blocker treatment efficacy of elderly patients with acute urinary retention. Methods Use of forward-looking monitoring and retrospective survey methodology, Choose January 1,2006 to January 1,2009 of acute urinary retention in 82 cases of elderly inpatients,Chronological order according to treatment group,39 cases were divided into control group,43 cases; Transurethral catheterization in both groups, stay catheter. The control group was treated with α1-receptor blocker hytrin (terazosin) and the application of antibiotics; the treatment group based on the above plus acupuncture therapy. Results The treatment group was 94.87% in the control group response rate was 76.74%, the two groups,P<0.05, the difference was significant. Conclusion al-receptor blockers combined with acupuncture treatment of elderly patients with acute urinary retention al-receptor blocker than simply good effects, synergistic effect, shortening the indwelling catheter time, avoid repeated urinary catheterization and reduce hospital infection, worthy to be popularized.     

α1-receptor blockers combined with acupuncture treatment efficacy analysis of elderly patients with acute urinary retention

Objective To explore acupuncture and al-receptor blocker treatment efficacy of elderly patients with acute urinary retention. Methods Use of forward-looking monitoring and retrospective survey methodology, Choose January 1,2006 to January 1,2009 of acute urinary retention in 82 cases of elderly inpatients,Chronological order according to treatment group,39 cases were divided into control group,43 cases; Transurethral catheterization in both groups, stay catheter. The control group was treated with α1-receptor blocker hytrin (terazosin) and the application of antibiotics; the treatment group based on the above plus acupuncture therapy. Results The treatment group was 94.87% in the control group response rate was 76.74%, the two groups,P<0.05, the difference was significant. Conclusion al-receptor blockers combined with acupuncture treatment of elderly patients with acute urinary retention al-receptor blocker than simply good effects, synergistic effect, shortening the indwelling catheter time, avoid repeated urinary catheterization and reduce hospital infection, worthy to be popularized.     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

2006年湖南省霍乱监测结果分析

目的 监测人群中霍乱病例和被霍乱弧菌污染的水体及食物,以便尽早采取预防控制措施,防止疫情扩散.方法 全省范围开展腹泻患者及外环境、食品监测,选择重点地区开展甲鱼霍乱弧菌污染状况专项监测.结果 2006年湖南省共登记腹泻患者111 526例,检测霍乱弧菌89 661例,检测率为80.39%,检出阳性4例,均为0139群霍乱弧菌感染;检测环境和食品样44 533份,其中水体35 113份,全部为阴性,水产品5377份,阳性16份,阳性率为0.30%,阳性标本为甲鱼和牛蛙,其他食品4043份,均为阴性;甲鱼专项监测2323份,检出阳性33份,阳性率为1.42%;霍乱毒素基因检测34株菌,20株为产毒株,占58.80%;药敏试验28株菌,均对诺氟沙星、环丙沙星、丁胺卡那霉素100%敏感,对强力霉素、复方新诺明的敏感率为92.86%.结论 甲鱼、牛蛙等水产品是湖南省发生霍乱的主要因素,应加强水产品的监测和卫生管理.     

新生儿抚触技术在产科中的应用体会

目的探讨新生儿抚触促进新生儿生长发育、融洽护患关系、提高产妇满意度的临床价值。方法选择2008年1月至2008年8月在我科住院正常分娩和剖宫产的健康儿200例,随机分为对照组100例,抚触组100例,观察新生几吃奶量、睡眠时间、排便时间和产妇满意度。结果抚触组新生儿吃奶量、睡眠时间、排便时间及产妇满意度均优于对照组。结论新生儿抚触既能促进新生儿生长发育,又能融洽护患关系,提高产妇满意度。是一种值得推广的简单易行效果好的新型护理技术。     

流程管理在见习期护士护理培训管理中的应用研究

目的 探讨流程管理应用于护士见习期护理培训管理与现代护理继续教育管理的适应关系.方法 采用自行制定的各项护理培训管理流程及考核量化表对2006年及2007年的各50名见习期护士分别从护理部考核、科护士长考核、护士长考核、责任带教护师评价、患者评价、转正率角度按照职业道德、操作能力、服务质量、绩效考核、适应能力等5项指标进行2次测评.结果 评价者对见习期护士的2次测评评分比较,差异明显.结论 流程管理在见习期护士护理培训管理中的实施有利于临床护理管理规范化、程序化、科学化,是适应新医疗环境下对见习期护士较好的护理培训管理方式.     

流程管理在见习期护士护理培训管理中的应用研究

目的 探讨流程管理应用于护士见习期护理培训管理与现代护理继续教育管理的适应关系.方法 采用自行制定的各项护理培训管理流程及考核量化表对2006年及2007年的各50名见习期护士分别从护理部考核、科护士长考核、护士长考核、责任带教护师评价、患者评价、转正率角度按照职业道德、操作能力、服务质量、绩效考核、适应能力等5项指标进行2次测评.结果 评价者对见习期护士的2次测评评分比较,差异明显.结论 流程管理在见习期护士护理培训管理中的实施有利于临床护理管理规范化、程序化、科学化,是适应新医疗环境下对见习期护士较好的护理培训管理方式.     

流程管理在见习期护士护理培训管理中的应用研究

目的 探讨流程管理应用于护士见习期护理培训管理与现代护理继续教育管理的适应关系.方法 采用自行制定的各项护理培训管理流程及考核量化表对2006年及2007年的各50名见习期护士分别从护理部考核、科护士长考核、护士长考核、责任带教护师评价、患者评价、转正率角度按照职业道德、操作能力、服务质量、绩效考核、适应能力等5项指标进行2次测评.结果 评价者对见习期护士的2次测评评分比较,差异明显.结论 流程管理在见习期护士护理培训管理中的实施有利于临床护理管理规范化、程序化、科学化,是适应新医疗环境下对见习期护士较好的护理培训管理方式.     

流程管理在见习期护士护理培训管理中的应用研究

目的 探讨流程管理应用于护士见习期护理培训管理与现代护理继续教育管理的适应关系.方法 采用自行制定的各项护理培训管理流程及考核量化表对2006年及2007年的各50名见习期护士分别从护理部考核、科护士长考核、护士长考核、责任带教护师评价、患者评价、转正率角度按照职业道德、操作能力、服务质量、绩效考核、适应能力等5项指标进行2次测评.结果 评价者对见习期护士的2次测评评分比较,差异明显.结论 流程管理在见习期护士护理培训管理中的实施有利于临床护理管理规范化、程序化、科学化,是适应新医疗环境下对见习期护士较好的护理培训管理方式.     

流程管理在见习期护士护理培训管理中的应用研究

目的 探讨流程管理应用于护士见习期护理培训管理与现代护理继续教育管理的适应关系.方法 采用自行制定的各项护理培训管理流程及考核量化表对2006年及2007年的各50名见习期护士分别从护理部考核、科护士长考核、护士长考核、责任带教护师评价、患者评价、转正率角度按照职业道德、操作能力、服务质量、绩效考核、适应能力等5项指标进行2次测评.结果 评价者对见习期护士的2次测评评分比较,差异明显.结论 流程管理在见习期护士护理培训管理中的实施有利于临床护理管理规范化、程序化、科学化,是适应新医疗环境下对见习期护士较好的护理培训管理方式.     

流程管理在见习期护士护理培训管理中的应用研究

目的 探讨流程管理应用于护士见习期护理培训管理与现代护理继续教育管理的适应关系.方法 采用自行制定的各项护理培训管理流程及考核量化表对2006年及2007年的各50名见习期护士分别从护理部考核、科护士长考核、护士长考核、责任带教护师评价、患者评价、转正率角度按照职业道德、操作能力、服务质量、绩效考核、适应能力等5项指标进行2次测评.结果 评价者对见习期护士的2次测评评分比较,差异明显.结论 流程管理在见习期护士护理培训管理中的实施有利于临床护理管理规范化、程序化、科学化,是适应新医疗环境下对见习期护士较好的护理培训管理方式.     

流程管理在见习期护士护理培训管理中的应用研究

目的 探讨流程管理应用于护士见习期护理培训管理与现代护理继续教育管理的适应关系.方法 采用自行制定的各项护理培训管理流程及考核量化表对2006年及2007年的各50名见习期护士分别从护理部考核、科护士长考核、护士长考核、责任带教护师评价、患者评价、转正率角度按照职业道德、操作能力、服务质量、绩效考核、适应能力等5项指标进行2次测评.结果 评价者对见习期护士的2次测评评分比较,差异明显.结论 流程管理在见习期护士护理培训管理中的实施有利于临床护理管理规范化、程序化、科学化,是适应新医疗环境下对见习期护士较好的护理培训管理方式.